Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Blood (2024) 144 (Supplement 1): 769.

https://doi.org/10.1182/blood-2024-193308

Published: 2024

Journal Articles

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Blood (2024) 144 (Supplement 1): 364.

https://doi.org/10.1182/blood-2024-194768

Published: 2024

Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Blood (2022) 140 (Supplement 1): 1501–1503.

https://doi.org/10.1182/blood-2022-169324

Published: 2022

Journal Articles

Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease

Sabine Kayser, Chiara Sartor, Marlise R. Luskin, Jonathan Webster, Fabio Giglio, Nydia Panitz, Andrew M. Brunner, Matthias Fante, Christoph Lutz, Daniel Wolff, Anthony D. Ho, Mark Levis, Richard F. Schlenk, Cristina Papayannidis

Blood (2021) 138 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2021-147446

Published: 2021

Journal Articles

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells

Blood (2020) 136 (13): 1507–1519.

https://doi.org/10.1182/blood.2019003654

Published: 2020

Includes: Supplemental data

Journal Articles

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Blood (2018) 132 (Supplement 1): 769.

https://doi.org/10.1182/blood-2018-99-118047

Published: 2018

Journal Articles

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Sophie Rabe, MSc, Eva Schitter, Tobias Roider, Peter-Martin Bruch, Carolin Kolb, Marta Stolarczyk, Jennifer Hüllein, Junyan Lu, Christof von Kalle, Christoph Lutz, Peter Dreger, Carsten Mueller-Tidow, Thorsten Zenz, MD, Wolfgang Huber, Sascha Dietrich, MD

Blood (2018) 132 (Supplement 1): 262.

https://doi.org/10.1182/blood-2018-99-116053

Published: 2018

Journal Articles

Characteristic Amino Acid and Energy Metabolism in AML Stem Cells As Revealed By Quantitative Multiplex Proteomics

Simon Raffel, MD, Jenny Hansson, Mattia Falcone, Christoph Lutz, Oliver Bischel, MD, Anthony D Ho, Jeroen Krijgsveld, Andreas Trumpp, Prof, PhD

Blood (2018) 132 (Supplement 1): 2780.

https://doi.org/10.1182/blood-2018-99-117046

Published: 2018

Journal Articles

Evaluation of Minimal Residual Disease (MRD) and MRD-Based Treatment Decisions in Ph/BCR-ABL Negative Adult Acute Lymphoblastic Leukemia (ALL): Experience from the German Multicenter Study Group for Adult ALL (GMALL)

Nicola Goekbuget, MD, Monika Brüggemann, Joachim Beck, MD, Christoph Faul, MD, Christian Koenecke, MD, Heinz A. Horst, MD PhD, Mustafa Kondakci, MD, Doris M. Kraemer, MD, PhD, Christoph Lutz, MD, Bernd Spriewald, MD, Michael Starck, MD, Christoph Rollig, MD MSC, Matthias Stelljes, MD, Andreas Viardot, MD, Ralph Wäsch, Knut Wendelin, MD, Hubert Serve, Michael Kneba, MD, Dieter Hoelzer, MD PhD

Blood (2017) 130 (Supplement 1): 139.

https://doi.org/10.1182/blood.V130.Suppl_1.139.139

Published: 2017

Journal Articles

Branched Chain Amino Acid Catabolism Restricts Alpha-Ketoglutarate Levels Resembling IDH mut -Driven DNA Hypermethylation in AML Stem Cells

Blood (2017) 130 (Supplement 1): 472.

https://doi.org/10.1182/blood.V130.Suppl_1.472.472

Published: 2017

Journal Articles

In-Depth Quantitative Multiplex Proteomics Reveal Subtype-Specific Differences Among Functionally Validated AML Stem Cell Populations

Simon Raffel, MD, Jenny Hansson, PhD, Carl Herrmann, PhD, Christoph Lutz, MD, Eike C. Buss, MD, Christian Thiede, MD, Anne Floercken, MD, Oliver Bischel, MD, Joerg Westermann, MD, Gerhard Ehninger, MD, Anthony D Ho, MD, Roland Eils, PhD, Jeroen Krijgsveld, PhD, Andreas Trumpp, PhD

Blood (2014) 124 (21): 2144.

https://doi.org/10.1182/blood.V124.21.2144.2144

Published: 2014

Journal Articles

Selective Persistence of Distinct Stem/B Leukaemic Stem Cells In Childhood Acute Lymphoblastic Leukaemia In Clinical Remission.

Christoph Lutz, MD, Petter Woll, PhD, Anders Castor, MD, PhD, Helen Ferry, PhD, Christina Jensen, PhD, Joanne Green, Helene Dreau, Michael Lutteropp, Anna Schuh, MD, PhD, Georgina Hall, MD, PhD, Chris Mitchell, MD, PhD, Jan Zuna, MD, PhD, Veronica Buckle, PhD, Sten Eirik W Jacobsen, MD, PhD, Tariq Enver, PhD

Blood (2010) 116 (21): 1585.

https://doi.org/10.1182/blood.V116.21.1585.1585

Published: 2010

Journal Articles

Complexity of Clonal Architecture in Childhood Acute Lymphoblastic Leukaemia

Kristina Anderson, Christoph Lutz, Frederik W. van Delft, Sue Colman, Yanping Guo, Helena Kempski, Anthony . Moorman, V, Tariq Enver, John Swansbury, Lyndal Kearney, Mel Greaves

Blood (2009) 114 (22): LBA-5.

https://doi.org/10.1182/blood.V114.22.LBA-5.LBA-5

Published: 2009

Journal Articles

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

Theis H. Terwey, MD, Gero Massenkeil, MD, Ingo Tamm, MD, Christoph Lutz, MD, Philipp Hemmati, MD, Stefan Neuburger, MD, Bernd Dorken, MD, Renate Arnold, MD

Blood (2006) 108 (11): 3004.

https://doi.org/10.1182/blood.V108.11.3004.3004

Published: 2006

Journal Articles

No Impact of Adverse Karyotype on Outcome after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Lymphoblastic Leukemia.

Ingo Tamm, MD, Gero Massenkeil, M.D., Mandy Wagner, Ph.D., Theis Terwey, M.D., Christoph Lutz, M.D., Stefan Neuburger, M.D., Christiane Bommert, M.D., Bernd Dörken, M.D., Renate Arnold, M.D.

Blood (2006) 108 (11): 3152.

https://doi.org/10.1182/blood.V108.11.3152.3152

Published: 2006

Journal Articles

Structural and Complex Chromosomal Aberrations Frequently Develop in Skin Fibroblasts after Allogeneic Stem Cell Transplantation.

Gero Massenkeil, MD, Petra Zschieschang, MD, Julia Pross, Ingo Tamm, MD, Stephan Neuburger, MD, Christoph Lutz, MD, Oliver Rosen, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2005) 106 (11): 1118.

https://doi.org/10.1182/blood.V106.11.1118.1118

Published: 2005

Journal Articles

Reduced Intensity Conditioning in Acute Leukemias: Long Term Follow-Up Confirms Sustained Complete Remissions.

Gero Massenkeil, MD, Stefan Neuburger, MD, Ingo Tamm, MD, Christoph Lutz, MD, Marion Nagy, PhD, Philipp Le Coutre, MD, Bernd Doerken, MD, Renate Arnold, MD

Blood (2004) 104 (11): 5147.

https://doi.org/10.1182/blood.V104.11.5147.5147

Published: 2004

Journal Articles

Matrix Glycoprotein Osteopontin Is a Stem Cell Niche Constituent That Constrains the Hematopoietic Stem Cell Pool Size.

Sebastian Stier, MD, Yon Ko, MD, Randolf Forkert, MD, Christoph Lutz, MD, Thomas Neuhaus, MD, Elisabeth Gruenewald, David Dombkowski, Susan R. Rittling, David T. Scadden, MD

Blood (2004) 104 (11): 664.

https://doi.org/10.1182/blood.V104.11.664.664

Published: 2004

Journal Articles

Donor Lymphocyte Infusions to Prevent Relapse in Acute Leukemias after Allogenic Stem Cell Transplantation.

Christoph Lutz, MD, Marion Nagy, PhD, Ingo Tamm, MD, Stefan Neuburger, MD, Bernd Doerken, MD, Renate Arnold, MD, Gero Massenkeil, MD

Blood (2004) 104 (11): 1642.

https://doi.org/10.1182/blood.V104.11.1642.1642

Published: 2004

Journal Articles

Ex vivo targeting of p21 Cip1/Waf1 permits relative expansion of human hematopoietic stem cells

Sebastian Stier, Tao Cheng, Randolf Forkert, Christoph Lutz, David M. Dombkowski, Jie Lin Zhang, David T. Scadden

Blood (2003) 102 (4): 1260–1266.

https://doi.org/10.1182/blood-2002-10-3053

Published: 2003

NARROW

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Characteristic Amino Acid and Energy Metabolism in AML Stem Cells As Revealed By Quantitative Multiplex Proteomics

Evaluation of Minimal Residual Disease (MRD) and MRD-Based Treatment Decisions in Ph/BCR-ABL Negative Adult Acute Lymphoblastic Leukemia (ALL): Experience from the German Multicenter Study Group for Adult ALL (GMALL)

Branched Chain Amino Acid Catabolism Restricts Alpha-Ketoglutarate Levels Resembling IDH mut -Driven DNA Hypermethylation in AML Stem Cells

In-Depth Quantitative Multiplex Proteomics Reveal Subtype-Specific Differences Among Functionally Validated AML Stem Cell Populations

Selective Persistence of Distinct Stem/B Leukaemic Stem Cells In Childhood Acute Lymphoblastic Leukaemia In Clinical Remission.

Complexity of Clonal Architecture in Childhood Acute Lymphoblastic Leukaemia

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

No Impact of Adverse Karyotype on Outcome after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Lymphoblastic Leukemia.

Structural and Complex Chromosomal Aberrations Frequently Develop in Skin Fibroblasts after Allogeneic Stem Cell Transplantation.

Reduced Intensity Conditioning in Acute Leukemias: Long Term Follow-Up Confirms Sustained Complete Remissions.

Matrix Glycoprotein Osteopontin Is a Stem Cell Niche Constituent That Constrains the Hematopoietic Stem Cell Pool Size.

Donor Lymphocyte Infusions to Prevent Relapse in Acute Leukemias after Allogenic Stem Cell Transplantation.

Ex vivo targeting of p21 Cip1/Waf1 permits relative expansion of human hematopoietic stem cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only